Individual holder
SWARTZ ROGER B
US·0 granted patents·3 pending applications·0 citations·filing 2020–2021
Individually held — no corporate assignee on record.
Top patents by PatentIndex Score
3 records- 0130US2022333130A1Episomal expression, genomic integrated lentiviral vector expression and mRNA expression of Potent Immunoglobulins Including Dimeric Immunoglobulin A1 and A2 via a furin cleavage site and 2A self-processing peptide to Enable Mucosal and Hematological Based Immunity or Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses.SWARTZ ROGER B·Filed 2021·Application pending·0 cites
- 0229US2022033851A1mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.SWARTZ ROGER B·Filed 2021·Application pending·0 cites
- 0325US2022064265A1Episomal Expression of Potent Immunoglobulins Derived from Human Blood or Convalescent Plasma to Enable Short term Vaccination / Immunization to COVID, COVID-19 and Mutants and Other Pandemic and non-Pandemic Viruses designed from Rapid FDA approval.SWARTZ ROGER B·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SWARTZ ROGER B files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →